(Q37849777)

24 August 2017

1 reference

title

Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease (English)

1 reference

24 August 2017

0 references

Basma M Ibrahim

1

1 reference

24 August 2017

Michael D Tsifansky

series ordinal

2

1 reference

24 August 2017

Yan Yang

series ordinal

3

1 reference

24 August 2017

Yoon Yeo

series ordinal

4

1 reference

24 August 2017

language of work or name

English

0 references

publication date

5 March 2011

1 reference

Expert Opinion on Drug Delivery

24 August 2017

published in

1 reference

24 August 2017

volume

8

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

451-466

1 reference

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Patterns of GI disease in adulthood associated with mutations in the CFTR gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis sputum: a barrier to the transport of nanospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Pharmacotherapy of the ion transport defect in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Emerging therapies for cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Emerging therapies in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

What's new in cystic fibrosis? From treating symptoms to correction of the basic defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Chronic macrolide therapy in inflammatory airways diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic Fibrosis Pulmonary Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Massive hemoptysis in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Effects of hyperosmotic stress on cultured airway epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhaled hypertonic saline as a therapy for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhaled mannitol improves lung function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhaled mannitol in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Status of gene therapy for cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis, vector-mediated gene therapy, and relevance of toll-like receptors: a review of problems, progress, and possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

US gene therapy in crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Progress and prospects: gene therapy clinical trials (part 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

21 January 2018

Nuclear factor-kappa B.

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Control of cystic fibrosis transmembrane conductance regulator expression by BAP31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhalable siRNA: potential as a therapeutic agent in the lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Sticky overhangs enhance siRNA-mediated gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Dry powder inhalers for optimal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Dry powder inhalers (DPIs)--a review of device reliability and innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Review of dry powder inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

A review of the development of Respimat Soft Mist Inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Aerosol devices and asthma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Extracellular barriers in respiratory gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Barrier properties of mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Micro- and macrorheology of mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

The genesis of cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mathematical modeling of molecular diffusion through mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

From mucins to mucus: toward a more coherent understanding of this essential barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Lessons from nature: "Pathogen-Mimetic" systems for mucosal nano-medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mucins, mucus, and sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Human cervical mucus and its interaction with sperm: a fine-structural view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Altering mucus rheology to"solidify" human mucus at the nanoscale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Diffusion of macromolecules and virus-like particles in human cervical mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Structural alterations of gene complexes by cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Antibiotic resistance of bacterial biofilms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Prevention of drug access to bacterial targets: permeability barriers and active efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Microparticles for inhalational delivery of antipseudomonal antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Controlled release antibiotics for dry powder lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cospray dried antibiotics for dry powder lung delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Progress and prospects: prospects of repeated pulmonary administration of viral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Nuclear entry of nonviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Ca2+-sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Progress and prospects: nuclear import of nonviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Nuclear targeting of viral and non-viral DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Non-viral nanovectors for gene delivery: factors that govern successful therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Endosomal disruptors in non-viral gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Gene delivery through the use of a hyaluronate-associated intracellularly degradable crosslinked polyethyleneimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

On the transport of lipoplexes through cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Nacystelyn enhances adenoviral vector-mediated gene delivery to mouse airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Mobility and stability of gene complexes in biogels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Sheddable coatings for long-circulating nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Screening effect of PEG on avidin binding to liposome surface receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Disruption of the mucus barrier by topically applied exogenous particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Functionalized positive nanoparticles reduce mucin swelling and dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis: ferreting with fibroblasts for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Developmental expression patterns of CFTR in ferret tracheal surface airway and submucosal gland epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Cystic fibrosis gene mutations and gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Viscoelastic Gel Formulations Enhance Airway Epithelial Gene Transfer with Viral Vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2011.561310

10.1517/17425247.2011.561310

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference